JSR Life Sciences について
私たちのことを学ぶ
JSR Life Sciences brings together the deep biochemical knowledge and understanding of human disease, expertise in drug discovery and development, and access to capital into a single, integrated framework that creates value for our customers.
JSR supports the drug discovery and development needs of our partners with tailored solutions that identifies and applies the right tools and technologies to support their unique therapeutic programs. From de-risking molecule selection and accelerating biologic development timelines, to increasing clinical success rates and developing in vitro diagnostics, JSR Life Sciences is committed to guiding our customers’ innovative science along the path to becoming life-saving medicines.
Accelerating Our Life Sciences Footprint
We offer our partners best-in-class research products and services for outsourced drug discovery and development. With our proprietary products and services and through our affiliate companies, JSR has a global presence including 28 sites in seven countries.
Our Affiliates
We leverage the core competencies of our affiliates to create integrated solutions that are designed to guide our partners’ programs from the lab through commercialization.
Crown Bioscience
Contract research organization with advanced technology for precision medicine
Similis Bio
Similis Bio jump-starts your biosimilar program with pre-qualified analytical methods, detailed reference product characterization & off-the-shelf assets.
MBL
Biomarker discovery for companion and in vitro diagnostics
KBI Biopharma
Global contract development and manufacturing organization with advanced analytical capabilities
JSR’s specialty life science research products include:
Amsphere A3, a protein A chromatography resin for advanced protein separation
Magnosphere hydrophilic and hydrophobic microparticles for research and in vitro diagnostics use
JSR Life Sciences is a business unit of JSR Corporation, a multinational advanced materials and solutions company based in Japan.
最新の JSR Life Sciences ニュース
JSR、抗体医薬精製用の新世代プロテインA担体「Amsphere™ A+」の販売開始
抗体医薬品は、がんや難病に対して有効性が⾼く、副作⽤が少ない効果的な治療薬として広く普及してきました。その製造プロセスは、二重特異性抗体や抗体薬物複合体などの実用化により、年々高度に複雑化しています。JSRグループが提供する「Amsphere™ A+」を使用することにより、要求が厳しく複雑化した抗体医薬製造プロセスにおいても、高い信頼性の確保と生産効率の向上が期待できます。
KBI Biopharma、FDAによる規制査察完了および世界有数の大手製薬会社との商用製造契約を延長拡大
KBI Biopharma、FDA規制査察完了と大手製薬会社との製造契約延長を発表。契約は2029年まで延長され、2億5000万ドルの追加購入が合意。
「MEBRIGHT™ ジェニタリウム Plus DR キット」に関する 学会共催セミナー開催のお知らせ
株式会社医学生物学研究所は、2024年6月27日から神戸で「MEBRIGHT™ ジェニタリウム Plus DR キット」についてのランチョンセミナーを開催します。